Physician profile
Alison Smith
NPI 1528493467
$8,534.57
in general payments reported to CMS, 2019-2025
27 companies · $1,434 in 2025
The $1,434 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,194 · 2022: $1,233 · 2023: $910 · 2024: $3,763 · 2025: $1,434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,109 · Travel and Lodging: $2,999.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,108.57 |
| Travel and Lodging | $2,999.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,222.62 | 2021-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Medtronic, INC. | $1,433.31 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $623.05 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $484.91 | 2021-2024 | Xarelto |
| Amgen INC. | $383.82 | 2021-2024 | Repatha |
| Pfizer INC. | $350.15 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $245.74 | 2021-2024 | |
| Boston Scientific Corporation | $229.89 | 2021-2023 | Watchman, Watchman Access System, Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.17 | 2021-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $176.99 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $173.58 | 2021-2024 | Verquvo |
| Amarin Pharma, INC. | $164.78 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $129.20 | 2021-2023 | Farxiga, Brilinta |
| United Therapeutics Corporation | $122.57 | 2024 | |
| Novo Nordisk INC | $100.53 | 2021-2024 | Ozempic, Rybelsus |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $73.42 | 2021-2022 | |
| Scpharmaceuticals INC. | $66.59 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $59.90 | 2023 | |
| Lundbeck LLC | $50.60 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $40.76 | 2023 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $40.57 | 2021 | |
| Daiichi Sankyo INC. | $34.97 | 2021 | |
| Esperion Therapeutics, INC. | $33.26 | 2021 | |
| Preventice Services, LLC | $27.44 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $23.61 | 2024 | Arcalyst |
| Philips North America LLC | $23.00 | 2023 | |
| Edwards Lifesciences Corporation | $22.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.